The framing of depression as a brain chemistry problem has helped a great many people. It reduced stigma. It provided an explanatory model that made medication feel rational rather than shameful. It moved depression out of the moral failure column and into the medical one, which was progress. What it also did — less intentionally — was narrow the investigation. If depression is a serotonin deficiency, you give something that raises serotonin. If that doesn't work, you try a different version of the same thing. If that doesn't work either, the patient tends to be told they have treatment-resistant depression, as though the problem is their resistance rather than the narrowness of the frame.
The research is now pointing somewhere more specific. Around 1 in 4 people with a depression diagnosis carry what is increasingly being characterised as an inflammatory subtype — a variant of the condition in which chronic low-grade inflammation is playing a central role in maintaining depressive symptoms, and in which antidepressants that target serotonin reuptake are not addressing the actual driver. The mechanism is established. The test that reveals it is one most people have already had. And the upstream cause — for a significant proportion of those affected — is not in the brain. It is in the gut.
What the inflammatory subtype
actually looks like.
The clinical case for a distinct inflammatory subtype of depression has been building for over a decade, with meta-analyses consistently finding elevated inflammatory markers — particularly C-reactive protein (CRP) and related cytokines — in people with depression compared to those without it. What has sharpened more recently is the clinical specificity: not everyone with depression has elevated inflammation, and the symptom profile of those who do is distinctive enough to be clinically identifiable.
The dominant features of inflammatory depression are not the features most people associate with the condition:
Inflammatory subtype — dominant features
- Anhedonia — inability to feel pleasure, reward, or motivation
- Profound fatigue disproportionate to activity
- Psychomotor slowing — thinking and movement feel effortful
- Persistent heaviness or numbness rather than sadness
- Poor response to standard antidepressant treatment
- Symptoms worse in the morning, slightly better later in the day
- Often coexists with chronic pain or gut symptoms
Classic presentation — more variable
- Low mood, sadness, tearfulness
- Negative thought patterns, rumination
- Sleep disturbance — early waking or hypersomnia
- Appetite changes
- Social withdrawal
- More likely to respond to serotonin-targeting medication
The distinction matters clinically because the symptom cluster that characterises inflammatory depression — the anhedonia, the fatigue, the psychomotor slowing — is precisely what predicts non-response to standard antidepressant treatment in people with elevated inflammatory markers. Someone cycling through their second or third antidepressant without meaningful improvement, who describes their depression less as sadness and more as a persistent inability to feel anything or generate any motivation, may not have treatment-resistant depression in the conventional sense. They may have unidentified inflammatory depression, and the treatment gap exists because the driver hasn't been addressed.
"The problem isn't that the antidepressant isn't working. The problem is that it's being applied to the wrong mechanism. You cannot correct a serotonin deficit by raising reuptake inhibition if the deficit exists because the immune system has redirected the raw material upstream."
How inflammation gets into the brain
and what it does to serotonin there.
The brain has a protective barrier between the bloodstream and neural tissue that controls, under most conditions, what crosses into the central nervous system. Inflammatory signalling proteins — cytokines — are among the exceptions. They reach the brain through direct transport across the barrier, through regions where the barrier is more permeable, and critically through the vagus nerve, which carries immune signals from the body directly to the brain stem. This is not a failure of the barrier. It is an evolved mechanism for the brain to receive information about the body's immune state.
Once those cytokine signals arrive, they activate microglia — the resident immune cells of the brain. Under normal conditions, microglia perform maintenance and surveillance. Under sustained inflammatory activation, they begin producing their own inflammatory chemicals, amplifying the signal locally, and — this is the key step — they upregulate an enzyme called indoleamine 2,3-dioxygenase, known as IDO.
IDO diverts tryptophan.
Tryptophan is the amino acid the brain uses to make serotonin. Under normal conditions, a significant proportion of dietary tryptophan travels the serotonin pathway. When IDO is upregulated by microglial activation driven by systemic inflammation, tryptophan is redirected into the kynurenine pathway instead — producing inflammatory metabolites rather than serotonin precursors. The serotonin production line doesn't malfunction. It runs short because the raw material has been diverted at source by an immune process that operates entirely upstream of where antidepressants act.
The kynurenine pathway that receives the redirected tryptophan produces its own downstream consequences. Some kynurenine metabolites — quinolinic acid in particular — are directly neurotoxic. They act as NMDA receptor agonists, contributing to excitotoxicity and neuronal damage in the hippocampus, the brain region most associated with emotional regulation, stress response, and memory. Chronic elevation of quinolinic acid has been found in the cerebrospinal fluid of people with depression and in those who have died by suicide at rates significantly above controls.
This is not a peripheral biochemical curiosity. It is a mechanism that begins in the gut, proceeds through systemic inflammation, reaches the brain via established immune-neural pathways, diverts a key neurotransmitter precursor, and produces neurotoxic metabolites as a byproduct. And it operates entirely outside the framework that most depression treatment is built around.
The number most people already have
that nobody connected to their mood.
C-reactive protein is produced by the liver in response to inflammatory signalling. It is measured in a standard blood panel. A significant proportion of people reading this will have had their CRP tested as part of a cardiovascular risk assessment or a routine check-up and will never have been told what it might mean for their mental health.
What 2 mg/L means in this context
A CRP of 2 mg/L or above is the threshold that has consistently emerged in the research literature as the cutoff for the inflammatory phenotype in people with depression. It is deliberately low — cardiovascular risk elevates concern above 3 mg/L, and acute infection can push CRP into the hundreds.
Many labs report a CRP of 2 mg/L as normal or borderline. In the cardiovascular context, that is broadly accurate. In the context of someone who has not responded well to antidepressants, a CRP above 2 mg/L is clinically significant — it substantially increases the probability that the inflammatory subtype is in play.
If you have been treated for depression without adequate response, and your most recent CRP was above 2 mg/L, that combination is the starting point for a different investigation — not a different antidepressant.
Why the gut is where
the investigation should begin.
Approximately 90% of the body's serotonin is produced in the gut — not the brain — by enterochromaffin cells in the gut lining, their production guided by microbial signals from the microbiome. The gut-brain axis is not a metaphor. It is a bidirectional communication network involving the vagus nerve, the enteric nervous system, the immune system, and the endocrine system, through which the state of the gut microbiome has direct consequences for mood, stress reactivity, and neurological function.
The specific mechanism by which gut dysbiosis drives inflammatory depression runs as follows. Disrupted gut microbiome composition — reduced diversity, depleted beneficial bacteria, elevated opportunistic pathogens — impairs the integrity of the gut lining. Tight junction proteins that normally seal the gut epithelium are compromised. Bacterial lipopolysaccharide (LPS), a cell wall component of gram-negative bacteria, crosses from the gut lumen into systemic circulation. LPS is one of the most potent activators of the innate immune system known. Its presence in the bloodstream triggers exactly the cytokine cascade that, via the pathway described above, reaches the brain, activates microglia, upregulates IDO, and diverts tryptophan.
This is the mechanism that makes gut health a mental health issue — not philosophically, but biochemically and in clinical sequence. The gut dysbiosis precedes the intestinal permeability. The intestinal permeability precedes the systemic inflammation. The systemic inflammation precedes the neuroinflammation. The neuroinflammation precedes the tryptophan diversion. The tryptophan diversion produces the serotonin deficit. And the antidepressant is applied at the final step of a six-step chain, to a deficit that is being actively maintained by processes five steps upstream.
The 90% serotonin problem
If 90% of serotonin is produced in the gut, and gut dysbiosis disrupts both the microbial signals that guide that production and the integrity of the gut lining that allows LPS to enter the bloodstream and drive neuroinflammation — then the gut is not a peripheral consideration in depression. It is the primary system to investigate when standard treatment is not working.
This does not mean every case of depression originates in the gut. It means that for the inflammatory subtype specifically, treating the brain without investigating the gut is addressing the endpoint of a chain while leaving every link in it intact.
MTHFR, folate, and the
neurotransmitter synthesis connection.
The inflammatory pathway is not the only biochemical route from impaired methylation to depression. There is a more direct one that operates independently of inflammation and connects the folic acid fortification conversation directly to mental health.
SAM — S-adenosylmethionine, the universal methyl donor produced in the methylation cycle — is required for the synthesis and metabolism of serotonin, dopamine, and noradrenaline. COMT, the methyltransferase enzyme that breaks down catecholamines, uses SAM directly. When the methylation cycle runs suboptimally — because MTHFR variants reduce folate conversion, because B12 status is functionally insufficient, because cofactor depletion from stress or poor diet has reduced SAM availability — neurotransmitter synthesis and metabolism are directly impaired, regardless of whether inflammation is present.
The specific connections:
- Serotonin synthesis requires adequate 5-MTHF (active folate) for the conversion of tryptophan to serotonin via the BH4 (tetrahydrobiopterin) pathway. BH4 is a cofactor for tryptophan hydroxylase, the enzyme that converts tryptophan to serotonin. BH4 synthesis depends on adequate folate and methylation capacity. MTHFR variants that impair folate conversion reduce BH4 availability and therefore serotonin synthesis capacity — independent of how much tryptophan is in the diet.
- Dopamine and noradrenaline methylation via COMT requires SAM. Slow COMT variants combined with reduced SAM availability produce catecholamine accumulation and dysregulated stress response — patterns clinically associated with anxiety and mood cycling rather than flat anhedonia, though the two often coexist.
- Unmetabolised folic acid from synthetic fortification competes with natural folate at receptor sites in people with MTHFR variants. Elevated UMFA has been associated in several studies with reduced folate bioavailability at the cellular level — potentially worsening the methylation deficit rather than addressing it, particularly in the populations most at genetic risk.
This is the direct connection between the folic acid fortification policy and mental health that the public health framing has not engaged with: mandatory addition of synthetic folic acid to the food supply, without study of its effects on the significant proportion of the population with MTHFR variants that impair its conversion, in a context where methylation dysfunction has direct downstream consequences for neurotransmitter synthesis. The intervention intended to support neural tube development may, for a specific and identifiable population, be worsening the very biochemical conditions associated with depression and anxiety.
What is established, what is strong,
what is still being worked out.
What to test and
what each layer tells you.
The investigation of inflammatory depression is not complex — but it requires looking at more than one layer simultaneously, because the chain from gut to brain involves multiple systems that each need their own window.
Practical steps — not a protocol,
a direction of investigation.
The practical response to suspecting the inflammatory subtype is not to abandon medical treatment. It is to bring a more complete picture to the clinical conversation — and to address the modifiable upstream drivers while that conversation happens.
Get your CRP and look at the number yourself
If you've been treated for depression without adequate response, and you've had a blood test in the past two years, find the result and look at the CRP. If it's above 2 mg/L — even if the report says normal or borderline — that number is clinically relevant to your treatment picture. Ask your GP or prescriber to consider it in the context of your antidepressant response. If you haven't had it tested recently, it costs very little to add to any blood draw.
Address the dietary inflammatory load
The evidence that dietary pattern changes reduce CRP and improve depressive symptoms in the inflammatory subtype is accumulating. The direction is consistent: reduce ultra-processed food, refined carbohydrates, seed oils, and pro-inflammatory dietary patterns; increase oily fish (EPA/DHA directly reduce neuroinflammation), colourful vegetables, fermented foods, and dietary diversity. This is not about restriction — it is about changing the inflammatory signal the gut and immune system are receiving. The Mediterranean dietary pattern has the best evidence base in the depression literature specifically.
Support the methylation cofactors
For anyone with known MTHFR variants or elevated homocysteine, ensuring adequate methylcobalamin B12, riboflavin (B2), zinc, and magnesium is a low-risk, low-cost step that directly supports the serotonin synthesis pathway via BH4 and the methylation cycle via SAM availability. Where synthetic folic acid from fortified food is a significant dietary component, shifting toward food-form folate from leafy greens and legumes reduces the UMFA burden on the conversion pathway.
Investigate the gut before deciding the brain is the problem
If depression has not responded adequately to antidepressant treatment, and particularly if it coexists with gut symptoms, chronic fatigue, or a history of food reactivity, the gut investigation should precede further medication escalation. The GI-MAP does not diagnose depression. It reveals whether the upstream driver of the inflammatory chain is present and characterises it specifically enough to allow targeted intervention.
A note on this post and mental health
This article discusses depression in a clinical and mechanistic context. It is not a substitute for medical or psychiatric care, and nothing here should be interpreted as advice to stop or change medication without consulting the prescribing clinician. If you are experiencing depression or a mental health crisis, please speak with your GP or contact a mental health service. In the UK, you can contact the Samaritans at any time on 116 123. The clinical information here is intended to expand the investigation, not to replace it.
If standard treatment hasn't worked,
the investigation hasn't been completed.
A 30-minute call costs nothing. It clarifies whether the functional testing picture — gut, inflammation, methylation, HPA — is worth mapping in your specific case, and which test is the most useful starting point for your clinical picture.
Book a Free Call Gut Health Testing Options